Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Delafloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 12/20 | 0.40 |
| ▸ | TOP2B | Q02880 | 10/20 | 0.40 |
| ▸ | TOP1 | P11387 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delafloxacin SCHEMBL29631821 | 1.00 | CYP3A4 (0.85) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| Delafloxacin SCHEMBL29379152 | 0.99 | CYP3A4 (0.86) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| Delafloxacin SCHEMBL29356726 | 0.99 | CYP3A4 (0.86) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| Delafloxacin SCHEMBL294694 | 0.99 | CYP3A4 (0.86) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| Delafloxacin SCHEMBL7248671 | 0.95 | CYP3A4 (0.82) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL30626293 | 0.92 | CYP3A4 (0.78) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL30626258 | 0.92 | CYP3A4 (0.78) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL29080643 | 0.92 | CYP3A4 (0.78) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL29080648 | 0.92 | CYP3A4 (0.78) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL28458194 | 0.92 | CYP3A4 (0.75) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170368055-A1 | METHODS FOR TREATING INFECTIONS | MELINTA THERAPEUTICS, LLC | 2017-12-28 | — | — | US | claimed |
| EP-3157510-A1 | ANTIMICROBIAL COMPOSITIONS WITH EFFERVESCENT AGENTS | Melinta Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| EP-3157633-A1 | METHODS FOR TREATING INFECTIONS | Melinta Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| US-20150366857-A1 | Antimicrobial Compositions with Effervescent Agents | MELINTA SUBSIDIARY CORP. | 2015-12-24 | — | — | US | claimed |
| US-20150366858-A1 | Methods for Treating Infections | MELINTA SUBSIDIARY CORP. (F/K/A MELINTA THERAPEUTICS, INC.) | 2015-12-24 | — | — | US | claimed |
| WO-2015196027-A1 | ANTIMICROBIAL COMPOSITIONS WITH EFFERVESCENT AGENTS | MELINTA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| WO-2015196076-A1 | METHODS FOR TREATING INFECTIONS | LI DANPING (US) | 2015-12-23 | — | — | WO | claimed |
| US-8648093-B2 | Salt and crystalline forms thereof of a drug | ABBVIE INC. (US) | 2014-02-11 | — | — | US | claimed |
| US-20130060040-A1 | Salt and Crystalline Forms Thereof of a Drug | ABBOTT LABORATORIES (US) | 2013-03-07 | — | — | US | claimed |
| US-8252813-B2 | Salt and crystalline forms thereof of a drug | ABBOTT LABORATORIES (US) | 2012-08-28 | — | — | US | claimed |
| US-20100286397-A1 | SALT AND CRYSTALLINE FORMS THEREOF OF A DRUG | MELINTA SUBSIDIARY CORP. (F/K/A MELINTA THERAPEUTICS, INC.) | 2010-11-11 | — | — | US | claimed |
| US-20100261703-A1 | SALT AND CRYSTALLINE FORMS THEREOF OF A DRUG | ABBOTT LABORATORIES (US) | 2010-10-14 | — | — | US | claimed |
| US-7728143-B2 | D-Glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylate trihydrate salt; crystal structure; dehydration | ABBOTT LABORATORIES (US) | 2010-06-01 | — | — | US | claimed |
| WO-2010056872-A2 | ANTIMICROBIAL COMPOSITIONS | RIB-X PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-20070249577-A1 | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures | RIB-X PHARMACEUTICALS, INC. | 2007-10-25 | — | — | US | claimed |
| US-20070238719-A1 | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures | RIB-X PHARMACEUTICALS, INC. | 2007-10-11 | — | — | US | claimed |
| US-20070238720-A1 | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures | RIB-X PHARMACEUTICALS, INC. | 2007-10-11 | — | — | US | claimed |
| EP-1802607-A2 | SALT AND CRYSTALLINE FORMS THEREOF OF A DRUG | ABBOTT LABORATORIES (US) | 2007-07-04 | — | — | EP | claimed |
| US-20070043019-A1 | Salt and crystalline forms thereof of a drug | MELINTA SUBSIDIARY CORP. (F/K/A MELINTA THERAPEUTICS, INC.) | 2007-02-22 | — | — | US | claimed |
| WO-2006042034-A2 | SALT AND CRYSTALLINE FORMS THEREOF OF A DRUG | ABBOTT LABORATORIES (US) | 2006-04-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366858-A1 | Methods for Treating Infections | LPO, FABP2, IL5 | CYP3A4 1842/4885CYP2C9 2438/4885ALDH1A1 1251/4885 |
| US-20150366857-A1 | Antimicrobial Compositions with Effervescent Agents | OPA1, FPR1, NOD2 | CYP3A4 1352/4885CYP2C9 1204/4885ALDH1A1 3525/4885 |
| US-20070238720-A1 | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures | MMP8, CLPP, MASP2 | CYP3A4 1472/4885CYP2C9 833/4885ALDH1A1 1382/4885 |
| US-20170368055-A1 | METHODS FOR TREATING INFECTIONS | LPO, FABP2, IL5 | CYP3A4 1842/4885CYP2C9 2438/4885ALDH1A1 1251/4885 |
| US-20070249577-A1 | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures | MMP8, CLPP, MASP2 | CYP3A4 1472/4885CYP2C9 833/4885ALDH1A1 1382/4885 |
| US-20070238719-A1 | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures | MMP8, CLPP, MASP2 | CYP3A4 1472/4885CYP2C9 833/4885ALDH1A1 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.